We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
“According to the National Prescription Audit, we have already made significant progress in reducing prescription rates over the past year,” said Attorney General Jeff Sessions. Read More
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate. Read More
PhRMA praised certain recommendations in a new report from the National Governors Association that lays out strategies governors are considering to lower drug prices, but questioned its suggestions on value-based pricing, a cap on Medicaid spending and more price transparency. Read More
The Justice Department and the Drug Enforcement Administration are proposing a major cut in production of the most commonly abused opioids in 2019. Read More
Endo lifted its stay of litigation against the FDA and is going ahead with a lawsuit challenging the agency’s policy on bulk drug compounding. Read More
Westminster Pharmaceuticals recalled two of its thyroid drugs after manufacturing them with APIs sourced from a Chinese supplier the FDA cited for GMP violations. Read More